Trial | NCT03509545  Report issue

Title

Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    20
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.
To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.
Study Started
Jun 30
2021
Anticipated
Primary Completion
Jun 30
2022
Anticipated
Study Completion
Jun 30
2022
Anticipated
Last Update
Jan 22
2020

Drug CHF Patients: ER Torsemide 40 mg

ER Torsemide 40mg given once daily to CHF patients

  • Other names: Demadex

Drug CHF Patients: Furosemide 40 mg

Stable CHF patients taking twice-daily 40 mg Furosemide

  • Other names: Lasix

CHF Patients: ER Torsemide 40 mg Experimental

CHF patients will be given 40 mg ER Torsemide

CHF Patients: Furosemide 40 mg Active Comparator

CHF patients are on 40 mg of Furosemide

Criteria 

Inclusion Criteria:

Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.

Exclusion Criteria:

Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.
No Results Posted